Johnson & Johnson (NYSE:JNJ) announces that it has received a $2.1B binding offer from private equity shop Platinum Equity for its LIfeScan glucose monitoring business.
The deadline for JNJ to accept the offer is June 15. If it does so, as expected, the transaction should close by year-end
READ FULL ARTICLE HERE